Program and Abstracts from the Canadian Digestive Diseases Week 2016

Table 3

High-quality data are needed to validate these conclusions.

Strategy for all patients	Cost	Incremental Cost	Effectiveness	Incremental Effectiveness	Incremental Cost-Effectiveness Ratio	Cost-Effectiveness Ratio	Cost-effectiveness characterization
T + H	9,150	0	0.9705	0	0	9,429	Reference strategy
T	9,296	145	0.8137	−0.1568	−927	11,424	dominated
H + T	9,786	635	0.9148	−0.0557	−11,413	10,697	dominated
H	11,123	1,973	0.5453	−0.4252	−4,640	20,399	dominated